We present evidence that steady achromatic adapting fields can produce response saturation in color-opponent pathways. We measured tvi (log increment threshold illuminance versus log background illuminance) functions at four test wavelengths (430, 490, 575, and 660 nm) and nine background illuminances from 4.0 to 5.6 log Td. Foveal, 2 degrees diameter, 1 s duration test stimuli were presented on a concentric, perceptually white (5128 degrees K color temperature), 7 degrees diameter, steady background. Thresholds were obtained by the method of adjustment, after which the test stimulus illuminances were increased 0.6 log unit and the subject estimated percentages of red, yellow, green, blue, and white. Average tvi slopes for two subjects were 2.06 for 430 nm, 1.6 for 490 nm, 1.11 for 575 nm and 1.34 for 660 nm, consistent with the estimated ratios of chromatic to achromatic sensitivity at the same wavelengths. Also, the percentage of white seen in the suprathreshold increments increased with increasing background illuminance despite increases in excitation purity. These findings imply that steady, intense, achromatic backgrounds can produce response saturation in color-opponent mechanisms at wavelengths across the visible spectrum. The saturation was more extreme at short wavelengths than at middle or long wavelengths, producing a tritanopic condition at the highest background illuminances. The tritanopia reduced color space to a predominately red-blue dichromacy, in agreement with previous findings. The results support a multistage opponent-color model in which precortical koniocellular and parvocellular opponent pathways interact to produce the observed red-green and yellow-blue color-opponent channels at a cortical level.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/josaa.22.002107 | DOI Listing |
Int J Nanomedicine
January 2025
Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, 72079, USA.
Poor aqueous solubility and bioavailability limit the translation of new drug candidates into clinical applications. Nanocrystal formulations offer a promising approach for improving the dissolution rate and saturation solubility. These formulations are applicable for various routes of administration, with each presenting unique opportunities and challenges posed by the physiological barriers.
View Article and Find Full Text PDFJ Strength Cond Res
December 2024
Jayhawk Athletic Performance Laboratory, Wu Tsai Human Performance Alliance, University of Kansas, Lawrence, Kansas.
Eserhaut, DA, DeLeo, JM, and Fry, AC. Blood flow restricted resistance exercise in well-trained men: Salivary biomarker responses and oxygen saturation kinetics. J Strength Cond Res 38(12): e716-e726, 2024-Resistance exercise with continuous lower-limb blood flow restriction (BFR) may provide supplementary benefit to highly resistance-trained men.
View Article and Find Full Text PDFBlood
January 2025
Fred Hutchinson Cancer Center, Seattle, Washington, United States.
Sclerosis is a highly morbid manifestation of chronic GVHD (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome measure (PRO) for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity.
View Article and Find Full Text PDFFluids Barriers CNS
January 2025
Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Background: Cerebral autoregulation is a robust regulatory mechanism that stabilizes cerebral blood flow in response to reduced blood pressure, thereby preventing cerebral ischaemia. Scientists have long believed that cerebral autoregulation also stabilizes cerebral blood flow against increases in intracranial pressure, which is another component that determines cerebral perfusion pressure. However, this idea was inconsistent with the complex pathogenesis of normal pressure hydrocephalus, which includes components of chronic cerebral ischaemia due to mild increases in intracranial pressure.
View Article and Find Full Text PDFAlzheimers Res Ther
January 2025
Radiology Department, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Background: The imbalance of glutamate (Glu) and gamma-aminobutyric acid (GABA) neurotransmitter system plays a crucial role in the pathogenesis of Alzheimer's disease (AD). Riluzole is a Glu modulator originally approved for amyotrophic lateral sclerosis that has shown potential neuroprotective effects in various neurodegenerative disorders. However, whether riluzole can improve Glu and GABA homeostasis in AD brain and its related mechanism of action remain unknown.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!